登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Apo-A1】

Apo-A1信息

英文名称:Apolipoprotein A-I
中文名称:载脂蛋白A-I
靶点别称:Epididymis Secretory Sperm Binding Protein,Apolipoprotein A-I(1-242),APOA1,ProapoA-I,Apo-AI,Apolipoprotein A1,Apo(A),ApoA-I,Apolipoprotein A-I,HPALP2
上市药物数量:0
临床药物数量:3
最高研发阶段:临床三期

Apo-A1产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
AP1-H5225
Human
Human Apo-A1 Protein, His Tag
ACRO质量管理体系
 
评论(0)
 

Apo-A1分子别名

Apolipoprotein A-I,APOA1,MGC117399

Apo-A1分子背景

ApoA1 is also known as apolipoprotein A-I, ApoA-I , and is the major protein component of high density lipoprotein (HDL) in plasma. It has a specific role in lipid metabolism. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterol acyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. In addition, it has been shown that ApoA1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.

Apo-A1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Pelacarsen IONIS-681257; ISIS-681257; TQJ-230 临床三期 Ionis Pharmaceuticals Inc, Akcea Therapeutics Inc 动脉粥样硬化, 肾脏疾病, 高脂蛋白血症, 心脏和血管疾病, 肝功能衰退, 主动脉瓣狭窄 详情
Zerlasiran SLN-360 临床二期 Silence Therapeutics Plc 动脉粥样硬化, 血脂障碍, 心脏和血管疾病, 高脂血症 详情
Fx-5A Fx-5A 临床一期 Kinemed Inc 心脏和血管疾病 详情

消息提示

请输入您的联系方式,再点击提交!

确定